Can targeted therapies offer safer and more efficient means to treat patients with acute myeloid leukemia (AML)? Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center in Buffalo, NY, shares a brief overview of AML and discusses how the treatment landscape for patients with AML has changed in recent years.
Click here to learn more.
In this expert interview, Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses donor selection for allogeneic stem cell transplantation in secondary acute myeloid leukemia (AML) patients…
Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses barriers to achieving racially diverse clinical trials for…
In an interview conducted at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy, Gail J. Roboz, MD, professor of medicine and director of the…
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the challenges and advancements in treating acute myeloid leukemia (AML) in patients who are unfit for intensive…
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses current therapeutic options for younger patients with acute myeloid leukemia. Dr Fathi notes that the approved guidance for…
In this “Practice Pearls” roundtable organized by Pharmacy Times, expert panelists discuss acute myeloid leukemia (AML) diagnosis and the various factors affecting decision-making for specialists treating patients with…
Tara Lin, MD, University of Kansas Medical Center, Kansas City, Kansas, discusses how she approaches choosing induction therapy for patients with treatment-related acute myeloid leukemia, emphasizing that fitness…
Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, highlights findings from the randomized phase…
